New approaches to the pharmacological management of generalized anxiety disorder

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50% of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use. Areas covered: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole). Expert opinion: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.

Original languageEnglish
Pages (from-to)175-184
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Anxiety Disorders
Pharmacology
S 20098
Antipsychotic Agents
Riluzole
Memantine
Therapeutics
Ondansetron
Serotonin Uptake Inhibitors
Expert Testimony
Valproic Acid
Anticonvulsants
Databases
Guidelines
Research

Keywords

  • Antipsychotics
  • Atypical
  • Generalized anxiety disorder
  • Pharmacotherapy
  • Unmet needs

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

New approaches to the pharmacological management of generalized anxiety disorder. / Buoli, Massimiliano; Caldiroli, Alice; Caletti, Elisabetta; Paoli, Riccardo Augusto; Altamura, Alfredo Carlo.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 2, 02.2013, p. 175-184.

Research output: Contribution to journalArticle

@article{f00e31b4277f404799d5d8cecefa04b6,
title = "New approaches to the pharmacological management of generalized anxiety disorder",
abstract = "Introduction: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50{\%} of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use. Areas covered: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole). Expert opinion: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.",
keywords = "Antipsychotics, Atypical, Generalized anxiety disorder, Pharmacotherapy, Unmet needs",
author = "Massimiliano Buoli and Alice Caldiroli and Elisabetta Caletti and Paoli, {Riccardo Augusto} and Altamura, {Alfredo Carlo}",
year = "2013",
month = "2",
doi = "10.1517/14656566.2013.759559",
language = "English",
volume = "14",
pages = "175--184",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - New approaches to the pharmacological management of generalized anxiety disorder

AU - Buoli, Massimiliano

AU - Caldiroli, Alice

AU - Caletti, Elisabetta

AU - Paoli, Riccardo Augusto

AU - Altamura, Alfredo Carlo

PY - 2013/2

Y1 - 2013/2

N2 - Introduction: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50% of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use. Areas covered: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole). Expert opinion: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.

AB - Introduction: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50% of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use. Areas covered: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole). Expert opinion: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.

KW - Antipsychotics

KW - Atypical

KW - Generalized anxiety disorder

KW - Pharmacotherapy

KW - Unmet needs

UR - http://www.scopus.com/inward/record.url?scp=84872714544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872714544&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.759559

DO - 10.1517/14656566.2013.759559

M3 - Article

VL - 14

SP - 175

EP - 184

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -